Cintia Roodveldt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9156220/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distinct responses of human peripheral blood cells to different misfolded protein oligomers. Immunology, 2021, 164, 358-371.	4.4	7
2	Immune Signaling Kinases in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). International Journal of Molecular Sciences, 2021, 22, 13280.	4.1	10
3	Differential Interactome and Innate Immune Response Activation of Two Structurally Distinct Misfolded Protein Oligomers. ACS Chemical Neuroscience, 2019, 10, 3464-3478.	3.5	7
4	lmmunization with αâ€synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model. Glia, 2018, 66, 191-205.	4.9	24
5	The chaperonin CCT inhibits assembly of α-synuclein amyloid fibrils by a specific, conformation-dependent interaction. Scientific Reports, 2017, 7, 40859.	3.3	48
6	Extracellular TDPâ€43 aggregates target MAPK/MAK/MRK overlapping kinase (MOK) and trigger caspaseâ€3/ILâ€18 signaling in microglia. FASEB Journal, 2017, 31, 2797-2816.	0.5	39
7	Commentary: Immunochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. Frontiers in Neurology, 2017, 8, 105.	2.4	1
8	Editorial: Molecular Chaperones and Neurodegeneration. Frontiers in Neuroscience, 2017, 11, 565.	2.8	6
9	The â€~Omics' of Amyotrophic Lateral Sclerosis. Trends in Molecular Medicine, 2016, 22, 53-67.	6.7	33
10	Chaperome screening leads to identification of Grp94/Gp96 and FKBP4/52 as modulators of the αâ€synucleinâ€elicited immune response. FASEB Journal, 2016, 30, 564-577.	0.5	13
11	Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1994-2003.	7.1	384
12	Chaperoned amyloid proteins for immune manipulation: αâ€6ynuclein/Hsp70 shifts immunity toward a modulatory phenotype. Immunity, Inflammation and Disease, 2014, 2, 226-238.	2.7	10
13	Hsp70 Oligomerization Is Mediated by an Interaction between the Interdomain Linker and the Substrate-Binding Domain. PLoS ONE, 2013, 8, e67961.	2.5	66
14	Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation. PLoS ONE, 2013, 8, e79160.	2.5	92
15	A Rationally Designed Six-Residue Swap Generates Comparability in the Aggregation Behavior of α-Synuclein and I²-Synuclein. Biochemistry, 2012, 51, 8771-8778.	2.5	22
16	Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12479-12484.	7.1	137
17	The Hsp70 Chaperone System in Parkinson's Disease. , 2011, , .		3
18	Glial Innate Immunity Generated by Non-Aggregated Alpha-Synuclein in Mouse: Differences between Wild-type and Parkinson's Disease-Linked Mutants. PLoS ONE, 2010, 5, e13481.	2.5	89

CINTIA ROODVELDT

#	Article	IF	CITATIONS
19	Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/α-synuclein complex by Hip. EMBO Journal, 2009, 28, 3758-3770.	7.8	110
20	Immunological features of αâ€ s ynuclein in Parkinson's disease. Journal of Cellular and Molecular Medicine, 2008, 12, 1820-1829.	3.6	84
21	The Latent Promiscuity of Newly Identified Microbial Lactonases Is Linked to a Recently Diverged Phosphotriesteraseâ€. Biochemistry, 2006, 45, 13677-13686.	2.5	258
22	High-throughput Screens and Selections of Enzyme-encoding Genes. , 2006, , 163-181.		0
23	Enzyme promiscuity: evolutionary and mechanistic aspects. Current Opinion in Chemical Biology, 2006, 10, 498-508.	6.1	550
24	The 'evolvability' of promiscuous protein functions. Nature Genetics, 2005, 37, 73-76.	21.4	742
25	Directed evolution of proteins for heterologous expression and stability. Current Opinion in Structural Biology, 2005, 15, 50-56.	5.7	122
26	Directed evolution of phosphotriesterase from Pseudomonas diminuta for heterologous expression in Escherichia coli results in stabilization of the metal-free state. Protein Engineering, Design and Selection, 2005, 18, 51-58.	2.1	96
27	Use of Full-Length Recombinant Calflagin and Its C Fragment for Improvement of Diagnosis of Trypanosoma cruzi Infection. Journal of Clinical Microbiology, 2005, 43, 5498-5503.	3.9	14
28	Shared Promiscuous Activities and Evolutionary Features in Various Members of the Amidohydrolase Superfamily. Biochemistry, 2005, 44, 12728-12736.	2.5	119
29	Purification of the 67-kDa lectin-like glycoprotein ofTrypanosoma cruzi, LLGP-67, and its evaluation as a relevant antigen for the diagnosis of human infection. FEMS Microbiology Letters, 2003, 220, 149-154.	1.8	9
30	Trypanosoma cruzi: identification of a galactose-binding protein that binds to cell surface of human erythrocytes and is involved in cell invasion by the parasite. Experimental Parasitology, 2002, 100, 217-225.	1.2	21
31	Alpha-Synuclein and the Immune Response in Parkinson's Disease. , 0, , .		1